Novo Nordisk (NVO) stock fell after announcing that CEO Lars Fruergaard Jørgensen will step down. BMO Capital Markets ...

Market Domination host Josh Lipton and guest host, Bullseye American Ingenuity Fund Portfolio Manager Adam Johnson, focus in ...

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

The pharmaceutical giant Novo Nordisk announced on Friday, May 16, 2025, that CEO Lars Fruergaard Jørgensen is stepping down amid mounting challenges for the obesity drug maker. The sudden leadership ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

(Reuters) -As Denmark’s Novo Nordisk (NYSE:NVO) shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United ...

The World Economic Forum recently spotlighted five healthcare breakthroughs, and at the top of the list was artificial intelligence. From surgical precision tools to real-time diagnostics, ...

Asian shares fell Monday and U.S. futures and the dollar weakened after Moody’sRatings downgraded the sovereign credit rating ...

Contrarian investing advice from biotech and pharmaceutical stock expert Hartaj Singh, Founding Partner of Tecumseh Partners ...

The Australian sharemarket is expected to open lower on Monday, as global investors react to Moody’s stripping the US of its top-notch credit rating ...

Moody’s lowered the US credit score to Aa1 from Aaa on Friday, joining Fitch Ratings and S&P Global Ratings in grading the ...

Novo Nordisk A/S has generally positive cash flows and wider gross margins than its peer group. Additionally, the company's ...